Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

Clicks: 304
ID: 6617
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #26 of 194 articles by views in journal of hepatocellular carcinoma

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI) Victor Hugo Fonseca de Jesus, Aldo Lourenço Abbade Dettino Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil Abstract: At the 2018 Gastrointestinal Cancer Symposium, sponsored by the American Society of Clinical Oncology, significant advances in the management of hepatocellular carcinoma (HCC) were announced. In intermediate-stage disease (Barcelona Clinic Liver Cancer stage B), interest in combining transarterial chemoembolization and sorafenib has been reignited as a consequence of the TACTICS trial. In advanced-stage disease (BCLC C), external-beam radiotherapy combined with transarterial chemoembolization proved to be superior to sorafenib in patients with portal vein thrombosis according to the START trial. Also, in patients with advanced-stage HCC, the CELESTIAL trial demonstrated survival benefits for patients undergoing treatment with cabozantinib in the second-line setting. Lastly, recent data on the activity of pembrolizumab in patients with HCC highlight the role of immunotherapy in the management of this disease in the years to come. Keywords: hepatocellular, carcinoma, liver, cancer, meeting, highlights, ASCO
Reference Key
victor2018updatejournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Victor Hugo Fonseca de Jesus;Aldo Lourenço Abbade Dettino and
Journal journal of hepatocellular carcinoma
Year 2018
DOI
10.2147/JHC.S171396
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.